May 13 (Reuters) - U.S. drugmaker Pfizer is considering its next move in a politically charged battle for control of Britain's AstraZeneca , after having a $106 billion approach rejected. Following is a summary of Reuters reports on the matter: TOP STORIES > UK lawmakers give Pfizer stick as it waves carrot at Astra > Pfizer's science vows to Britain: promise or placebo? > BREAKINGVIEWS-AstraZeneca is no one's property > UK labs play shrinking role in AstraZeneca drug portfolio > UK's Cameron says making good progress on Pfizer guarantees
> UK finance minister ready for "hard negotiation" with Pfizer > In AstraZeneca fight, valuing drugs as much art as science > AstraZeneca fights bid by predicting sales surge - eventually > EU likely to block any UK intervention in Astra bid -lawyers > Maryland, Delaware governors concerned about Pfizer-Astra deal
> Fear of Pfizer-AstraZeneca job cuts voiced by U.S. lawmakers
> In $100 bln fight, R&D site marks political frontline GRAPHICS > AstraZeneca share price vs employees: http://link.reuters.com/gaq29v > AstraZeneca share price performance and valuation: http://link.reuters.com/nyp29v > Top 20 pharmaceutical companies by sales: http://link.reuters.com/guk98v > World pharmaceutical companies valuation: http://link.reuters.com/gaz97s
(Compiled by Pravin Char)
Our Standards: The Thomson Reuters Trust Principles.
